Live Updates > Live Update Details
2026-04-04 02:16:58
[Bank of America: Eli Lilly's New Drug Approval Could Make It a Leader in the GLP-1 Market] Analysts at Bank of America say that the approval of Eli Lilly's oral weight-loss drug could give it a leading position in the GLP-1 competition. These analysts noted, "Given its ease of use, we believe this product will become the first choice among oral GLP-1 products." The pill, named Foundayo, was approved slightly earlier than these analysts expected. They believe investors will be watching to see if Foundayo will impact market demand for Eli Lilly's other weight-loss drug, Zepbound. Currently, these analysts have not raised their full-year revenue forecast for Eli Lilly, but have raised their target price by $1 to $1294.
